Welcome to Mondobiotech’s Investor Relations
mondoBIOTECH holding AG (SIX Swiss Exchange ticker symbol: RARE) is an independent Swiss biotech company discovering drugs for patients suffering from rare diseases through its proprietary Search & Match methodology.
In Search & Match mondobiotech’s scientists combine their unique knowledge of biologically active human peptides with advanced technology solutions delivering remedies for rare diseases to licensing partners.
The company has so far discovered more than 300 medicinal product candidates for further exploration in as many as possible of the 7000 rare diseases. Its products feature two major characteristics: being biologically active peptides of human origin and have platform potentiality for at least 3 orphan indications.
Investor Relations Contacts
mondoBIOTECH holding AG
Investor & External Relations
T. +41 (0)840 200 010
F. +41 (0)840 200 011
mondoBIOTECH holding AG (SIX: RARE) comments today about the acquisition of a minority stake of Pierrel Research International AG by Fin Posillipo S.p.A.in connection to the transaction between mondoBIOTECH and Pierrel S.p.A signed on the 24/01/2013
mondoBIOTECH holding AG (SIX: RARE) announces today its financial results for 2012 and the completion of the due diligence in connection with the business combination with the CRO division of Pierrel SpA
mondobiotech holding AG (SIX:RARE) announces the exercise of the convertion rights by BioPharma Invest AG
mondoBIOTECH holding AG and Pierrel SpA have entered into a binding agreement for a business combination.
mondoBIOTECH holding AG (SIX:RARE) announces that in 2013 Paolo Barbieri, CFO, will leave the Company to pursue new challenges in the Asset Management arena.